Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Grove City, Ohio Clinical Trials

A listing of Grove City, Ohio clinical trials actively recruiting patient volunteers.

RESULTS

Found (1069) clinical trials

Efficacy and Safety of Artacent for Treatment Resistant Lower Extremity Venous and Diabetic Ulcers

This study is to document the efficacy of Artacent Human Amniotic Membrane (Artacent) in the treatment of diabetic and vascular lower extremity ulcers. The study will add to the currently available literature by also assessing the impact of treatment on quality of life and on heal economic outcomes. Finally the ...

Phase N/A

0.0 miles

Learn More »

Behavior of Infants Fed Formula Supplemented With Prebiotics

To observe the effects of partially hydrolyzed formula supplemented with oligosaccharides on symptoms of formula intolerance in healthy term infants.

Phase N/A

0.0 miles

Learn More »

Phase N/A

0.0 miles

Learn More »

GlaxoSmithKline's (GSK) Safety and Immunogenicity Study of GSK Meningococcal Group B and 13-valent Pneumococcal Vaccines Administered Together With Routine Infant Vaccines in Healthy Infants

This study will be divided into 3 timepoints: Epoch 1- Primary- From day 1 to day 301 Epoch 2-Secondary-From day 301 to day 331 Epoch 3-Safety follow up -From day 331 to study end (day 661) In addition to receiving the study vaccines, infants will also receive non-study vaccines such ...

Phase

0.0 miles

Learn More »

Efficacy Safety and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults

This randomized, observer-blind, placebo-controlled multicenter, Phase 3 study will be conducted at multiple sites. The composition of the Quadrivalent VLP Influenza Vaccine to be used in this study includes a mix of recombinant H1, H3, and two B hemagglutinin proteins expressed as VLPs for the 2017-2018 influenza virus strains. Approximately ...

Phase

0.0 miles

Learn More »

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects

This is a phase II, multicenter, randomized, double-blind, placebo and active controlled dose ranging 5-arm parallel group study to identify the optimal dose of CHF 781 pMDI with respect to lung function and other clinical efficacy and safety outcomes. After a 2 week run-in period under rescue albuterol as needed ...

Phase

0.0 miles

Learn More »

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

The goal of asthma treatment is to achieve and maintain asthma control and to reduce the future risk of exacerbations. Inhaled corticosteroids (ICS) are considered as the most effective anti- inflammatory treatment for all severities of persistent asthma. For children >=5 years of age and adolescents whose asthma is uncontrolled, ...

Phase

0.0 miles

Learn More »

Growth and Safety Study of an Infant Formula for Healthy Term Infants

This study is a randomized, controlled, double-blind, study of healthy term formula fed (FF) infants. FF infants will be randomized to receive either a experimental infant formula, formulated for healthy term infants (Formula B) or a commercially available infant formula for healthy term infants (Formula A). Infants will consume the ...

Phase N/A

0.0 miles

Learn More »

Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment

This study is a 2-treatment period, randomized, multicenter parallel-group study. The overall purpose of this study is to provide long- term safety data for fevipiprant (QAW039) (Dose 1 and Dose 2), compared with placebo, when added to the Global Initiative for Asthma (GINA) steps 3, 4, and 5 standard-of-care (SoC) ...

Phase

0.0 miles

Learn More »

Efficacy and Safety of Sotagliflozin Versus Placebo in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

Up to 60 weeks (Screening phase of up to 2 weeks, a 4-week Lantus titration/single-blind placebo Run-in phase), a 52-week double blind Treatment Period, and a 2-week post-treatment Follow-up Period.

Phase

0.48 miles

Learn More »